Elevation of activated platelet-dependent chemokines in patients with anti-CD20 monoclonal antibody (rituximab)-treated non-Hodgkin's lymphoma

Clinical and Applied Thrombosis/Hemostasis

Volumn 13, Issue 2, 2007, Pages 206-212

  Nomura, Shosaku ^a   Ishii, Kazuyoshi ^a   Kamitsuji, Yuka ^b   Uoshima, Nobuhiko ^b   Ishikawa, Emiko ^c   Kitayama, Hitoshi ^c   Hayashi, Kunio ^c  

^a Kishiwada City Hospital   (Japan)

^b MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^c HOSHIGAOKA KOSEINENKIN HOSPITAL   (Japan)

Author keywords

Chemokine; Non Hodgkin's lymphoma; Rituximab

Indexed keywords

CHEMOKINE; CHEMOTACTIC FACTOR; EOTAXIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; INTERLEUKIN 8; ONCOPROTEIN; RANTES; RITUXIMAB; STROMAL CELL DERIVED FACTOR 1;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; STROMA; THROMBOCYTE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; BLOOD PLATELETS; CHEMOKINES; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED;

EID: 34047275408     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029606295583     Document Type: Article

References (56)

1. Luster AD Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med. 1998 ; 338: 436-445.
2. Wong MM, Fish EN Chemokines: attractive mediators of the immune response. Semin Immunol. 2003 ; 15: 5-14.
3. Teruya-Feldstein J., Tosato G., Jaffe ES The role of chemokines in Hodgkin's disease. Leukemia Lymphoma. 2000 ; 38: 363-371.
4. Baggiolini M., Dewald B., Moser B. Human chemokines: an update. Annu Rev Immunol. 1997 ; 15: 675-705.
5. Rollins BJ, Yoshimura T., Leonard EJ, Pober JS Cytokine-activated human endothelial cells synthesize and secrete a monochemoattractant, MCP-1/JE. Am J Pathol. 1990 ; 136: 1229-1233.
6. Colotta F., Borre A., Wang JM, et al. Expression of a monocyte chemotactic cytokine by human mononuclear phagocytes. J Immunol. 1992 ; 148: 760-765.
7. Tedla N., Palladinetti P., Wakefield D., Lloyd A. Abundant expression of chemokines in malignant and infective human lymphadenopathies. Cytokine. 1999 ; 11: 531-540.
8. Husson H., Carideo EG, Cardoso AA, et al. MCP-1 modulates chemotaxis by follicular lymphoma cells. Br J Haematol. 2001 ; 115: 554-562.
9. Baggiolini M., Dewald B., Moster B. Interleukin-8 and related chemotactic cytokines - CXC and CC chemokine. Adv Immunol. 1994 ; 55: 97-179.
10. Kameyoshi Y., Dorschner A., Mallet AI, Christophers E., Schroder JM Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med. 1992 ; 176: 587-592.
11. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A., Springer TA A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med. 1996 ; 184: 1101-1109.
12. Ahuja SK, Murphy PM The CXC chemokines growth-regulated oncogene (GRO)α, GRO β, GRO γ, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J Biol Chem. 1996 ; 271: 20545-20550.
13. Power CA, Clemetson JM, Clemetson KJ, Wells TN Chemokine and hemokine receptor mRNA expression in human platelets. Cytokine. 1995 ; 7: 479-482.
14. Klinger MH, Wilhelm D., Bubel S., Sticherling M., Schroder JM, Kuhnel W. Immunocytochemical localization of the chemokines RANTES and MIP-1 within human platelets and their release during storage. Int Arch Allergy Immunol. 1995 ; 107: 541-546.
15. Landis S., Murray T., Bolden S., Wingo PA Cancer statistics. 1998. CA Cancer J Clin. 1998 ; 48: 6-29.
16. Harris NL, Jaffe ES, Stein H., et al. Lymphoma classification proposal: Clarification. Blood. 1995 ; 85: 857-860.
17. Anderson KC, Bates MP, Slaughenhoupt BL Pinkus GS, Schlossman SF, Nadler LM Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood. 1984 ; 63: 1424-1433.
18. Einfeld DA, Brown JP, Valentine MA Clark EA, Ledbetter JA Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 1988 ; 7: 711-717.
19. Tedder TF, Engel P. CD20: A regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994 ; 15: 450-454.
20. Stashenko P., Nadler LM, Hardy R., Schlossman SF Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980 ; 125: 1678-1685.
21. Press OW, Appelbaum F., Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 1987 ; 69: 584-591.
22. Knox SJ, Goris ML, Trisler K., et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996 ; 2: 457-470.
23. Coiffier B., Haioun C., Ketterer N., et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998 ; 92: 1927 -1932.
24. McLaughlin P., Grillo-Lopez A., Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a fourdose treatment program. J Clin Oncol. 1998 ; 16: 2825-2833.
25. Davis TA, White CA, Grillo-Lopez A., et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol. 1999 ; 17: 185-187.
26. Shan D., Ledbetter JA, Press OW Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother. 2000 ; 48: 673-683.
27. Golay J., Zaffaroni L., Vaccari T., et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000 ; 95: 3900-3908.
28. Reff ME, Carner K., Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994 ; 83: 435-445
29. Christiansen I., Sundstrom C., Kalkner KM, et al. Serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) are elevated in advanced stages of non-Hodgkin's lymphomas. Eur J Haematol. 1999 ; 62: 202-209.
30. Bogetto L., Gabriele E., Cariati R., et al. Bidirectional induction of the cognate receptor-ligand α4/VCAM-1 pair defines a novel mechanism of tumor intravasation. Blood. 2000 ; 95: 2397-2406.
31. Haznedaroglu IC, Benekli M., Ozcebe O., et al. Serum L-selectin and P-selectin levels in lymphomas. Haematologica. 2000 ; 30: 27-30.
32. Koch AE, Kunkel SL, Harlow LA, et al. Macrophage inflammatory protein-1: a novel chemokine cytokine for macrophages in rheumatoid arthritis. J Clin Invest. 1994 ; 93: 921-928.
33. Pattison J., Nelson PJ, Huie P., et al. RANTES chemokine expression in cell-mediated transplant rejection of the kidney. Lancet. 1994 ; 343: 209-211.
34. Cocchi F., DeVico AL, Garzino-Demo A. Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995 ; 270: 1811-1815.
35. Holme PA, Muller F., Solum NO, Brosstad F., Froland SS, Aukrust P. Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB J. 1998 ; 12: 79-89.
36. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999 ; 17: 268-276
37. Hainsworth JD, Litchy S., Burris HA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol. 2002 ; 20: 4261-4267.
38. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete response are not predictive of progression-free survival. J Clin Oncol. 2002 ; 20: 1288-1294.
39. Matsushima K., Larsen CG, DuBois GC, Oppenheim JJ Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med. 1989 ; 169: 1485-1490.
40. Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA. 1990 ; 87: 5134-1538.
41. Schaniel C., Pardali E., Sallusto F., et al. Activated murine B lymphocytes and dendritic cells produce a novel CC chemokine which acts selectively on activated T cells. J Exp Med. 1998 ; 188: 451-463.
42. Loetscher P., Seitz M., Clark-Lewis I., Baggiolini M., Moser B. Activation of NK cells by CC chemokines. Chemotaxis, Ca 2+ mobilization, and enzyme release. J Immunol. 1996 ; 156: 322-327.
43. Maghazachi AA, AI-Aoukaty A., Schall TJ CC chemokines induce the generation of killer cells from CD56+ cells. Eur J Immunol. 1996 ; 26: 315-319.
44. Xu LL, Warren MK, Rose WL Gong W., Wang JM, et al. Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro. J Leukoc Biol. 1996 ; 60: 365-371.
45. Taub DD, Ortaldo JR, Turcovski-Corrales SM, Key ML, Longo DL, Murphy WJ Beta chemokines constimulate lymphocyte cytolysis, proliferation, and lymphokine production. J Leukoc Biol. 1996 ; 59: 81-89.
46. Adema GJ, Hartgers F., Verstraten R., et al. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature. 1997 ; 387: 713-717.
47. Kim JJ, Nottingham LK, Sin JI, et al. CD8 positive T cells influence antigen-specific luumune responses through the expression of chemokines. J Clin Invest. 1998 ; 102: 1112-1124.
48. Appay V., Dunbar PR, Cerundolo V., McMichael A., Czaplewski L., Rowland-Jones S. RANTES activates antigen-specific cytotoxic T lymphocytes in a mitogen-like manner through cell surface aggregation. Int Immunol. 2000 ; 12: 1173-1182.
49. Walz A., Burgener R., Car B., Baggiolini M., Kunkel SL, Strieter RM Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med. 1991 ; 174: 1355-1362.
50. Biswas P., Delfanti F., Bernasconi S., et al. Interleukin-6 induces monocyte chemotactic protein-1 in peripheral mononuclear cells and in the U937 cell line. Blood. 1998 ; 91: 258-265.
51. Winkler U., Jensen M., Manzke O., Schulz H., Diehl V., Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood. 1999 ; 94: 2217-2224.
52. Power CA, Furness RB, Brawand C., Wells TN Cloning of a full-length cDNA encoding the neutrophil-activating peptide ENA-78 from human platelets. Gene. 1994 ; 151: 333-334.
53. Boehlen F., Clemetson KJ Platelet chemokines and their receptors: what is their relevance to platelet storage and transfusion practice? Transfus Med. 2001 ; 11: 403-417.
54. Nomura S., Tandon NN, Nakamura T., Cone J., Fukuhara S., Kambayashi J. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis. 2001 ; 158: 277-287.
55. Matsumoto N., Nomura S., Kamihata H., Kimura Y., Iwasaka T. Increased level of oxidized LDL-dependent monocyte-derived microparticles in acute coronary syndrome. Thromb Haemost. 2004 ; 91: 146-154.
56. Horsewood P., Hayward CP, Warkentin TE, Kelton JG Investigation of the mechanisms of monoclonal antibody-induced platelet activation. Blood. 1991 ; 78: 1019-126.